Boothbay Fund Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Boothbay Fund Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$272K	Hold	4,324	–	–	﹤0.01%	1779
2026 Q1	$303K	Hold	4,324	–	–	﹤0.01%	1605
2025 Q4	$354K	Sell	4,324 -7,793	-64%	-$582K	0.01%	1341
2025 Q3	$720K	Sell	12,117 -17,731	-59%	-$873K	0.01%	983
2025 Q2	$1.21M	Sell	29,848 -91,425	-75%	-$4.11M	0.02%	626
2025 Q1	$6.23M	Sell	121,273 -35,130	-22%	-$1.74M	0.16%	172
2024 Q4	$8.66M	Sell	156,403 -119,160	-43%	-$5.41M	0.21%	127
2024 Q3	$9.06M	Buy	275,563 +75,469	+38%	+$2.12M	0.21%	113
2024 Q2	$5.44M	Buy	200,094 +24,582	+14%	+$827K	0.13%	206
2024 Q1	$6.38M	Buy	175,512 +63,740	+57%	+$1.87M	0.12%	159
2023 Q4	$2.26M	Hold	111,772	–	–	0.06%	433
2023 Q3	$1.99M	Buy	+111,772	New	+$1.98M	0.05%	502

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boothbay Fund Management's TARS Position: Q2 2026 in Review

Boothbay Fund Management held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 4,324 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #1779.

Boothbay Fund Management first reported a position in TARS in Q3 2023 and has held it in 12 quarters since. The position peaked at $9.06M in Q3 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Boothbay Fund Management held 4,324 shares of Tarsus Pharmaceuticals worth $272K as of Q2 2026.
Boothbay Fund Management left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
Tarsus Pharmaceuticals made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1779 holding.
Boothbay Fund Management first reported a position in Tarsus Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Boothbay Fund Management's Tarsus Pharmaceuticals position peaked at $9.06M in Q3 2024.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.